ACELYRIN
Founded Year
2020Stage
Series C | AliveTotal Raised
$550MLast Raised
$300M | 8 mos agoAbout ACELYRIN
ACELYRIN is a biopharma company focused on providing patients with new treatment options by identifying, acquiring, and accelerating the development and commercialization of drug candidates. It focuses on axial spondyloarthritis, hidradenitis suppurativa, psoriatic arthritis, and uveitis. The company was founded in 2020 and is based in Woodland Hills, California.
Missing:ACELYRIN'sProduct Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing:ACELYRIN'sProduct & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
LatestACELYRINNews
Apr 18, 2023
April 18, 2023 During what has become one of the slowest IPO years in recent memory, cancer immunotherapy company Cytomed Therapeutics Ltd. debuted on Nasdaq, raising $9.65 million, while inflammatory disease firm Acelyrin Inc. filed to list its stock for a potential $100 million. Up to this point, there were only six biopharma IPOs completed this year – the fewest since 2013. Cytomed, which priced 2.4 million shares at $4 apiece, is now the seventh for 2023, and the fifth on Nasdaq. Two other IPOs have closed on Chinese markets.
ACELYRINFrequently Asked Questions (FAQ)
When was ACELYRIN founded?
ACELYRIN was founded in 2020.
Where is ACELYRIN's headquarters?
ACELYRIN's headquarters is located at 23371 Mulholland Drive, Woodland Hills.
What is ACELYRIN's latest funding round?
ACELYRIN's latest funding round is Series C.
How much did ACELYRIN raise?
ACELYRIN raised a total of $550M.
Who are the investors of ACELYRIN?
Investors of ACELYRIN include Westlake Village BioPartners, Decheng Capital, Tybourne Capital Management, Samsara BioCapital, Marshall Wace Asset Management and 9 more.
Who are ACELYRIN's competitors?
Competitors of ACELYRIN include Asieris Pharma.
Compare ACELYRIN to Competitors
Alumis, fka Esker Therapeutics, is a precision medicine company reimagining discovery, development, and treatment approaches for autoimmune diseases.
BioMimetic Pharmaceuticals (BMTI) is a biopharmaceutical company focused on the development, commercialization and ultimate marketing of protein therapeutics for tissue and organ regeneration. The Company's lead technologies are for the healing and restoration of bone and other tissues. Its lead products are based on recombinant human platelet-derived growth factor BB (rhPDGF-BB). In March 2013, BioMimetic Therapeutics was acquired by Wright Medical Group. The valuation of BioMimetic Therapeutics was $190 million. Other terms of the deal were not released.
回路微调疗法生物科技(纳斯达克:alg)》ogy company developing therapeutic agents to treat significant liver diseases. The company is discovering and developing new classes of molecules that interact directly with disease causing modalities, such as viral encoded proteins and nucleic acids, as well as oncogenes and the resultant proteins in the case of its cancer indications. The company is also pursuing therapeutic agents aimed at activation of the patients' immune system, in an effort to create lasting benefits for diseases that cause significant morbidity and mortality.
Ambrx (NYSE: AMAM) is a clinical-stage biotechnology company focused on discovering and developing first-in-class and best-in-class optimized protein therapeutics known as bio-conjugates. The company's proprietary technology platforms enable the attachment of pharmaceutically active molecules to specific sites within proteins more precisely than prior generations of bio-conjugates and with precision similar to that used to design small-molecule drugs. Ambrx has developed a pipeline of novel product candidates that include antibody-drug conjugates, or ADCs, bi- and multi-specific drug conjugates, and long-acting therapeutic proteins.
Asieris Pharma (688176.SH) is a Chinese company focused on developing cancer treatment technology. The company is developing a repurposed oral inhibitor of MetAP2, a spectrum antibiotic that has been shown to have an anti-angiogenesis effect. It will be tested as a treatment for patients with relapsed non-muscle invasive bladder cancer (NMIBC). The firm was founded in 2013 and is based in Shanghai, China.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.